<i>In vitro</i> assessment of the impact of 30 CYP2C19 variants on citalopram metabolism
These CYP2C19 variants require specific attention from physicians and researchers, as their altered metabolic activities may influence the safety and efficacy of citalopram treatment. This work greatly expands the previously underexplored knowledge about the metabolic activities of rare or novel CYP2C19 variants in relation to citalopram medication. These findings may further facilitate the precision use of citalopram in personalized medicine.
Authors
- Xiaoxia Hu (ORCID: https://orcid.org/0000-0002-8807-5036)
- Junwei Li (ORCID: https://orcid.org/0000-0002-0727-7112)
- Peng Wang (ORCID: https://orcid.org/0000-0001-9325-359X)
Institutions
- Wenzhou Medical University (CN)
- Jinhua Academy of Agricultural Sciences (CN)
- Guang Fu Hospital (CN)
- Jinhua Central Hospital (CN)
Publication Details
- Journal
- PeerJ
- Published
- 2025-09-29
- DOI
- https://doi.org/10.7717/peerj.20027
- Primary Topic
- Pharmacogenetics and Drug Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Wenzhou Medical University
- National Health Commission of the People's Republic of China